MedTrace Logo

A Study in Parkinson's Disease in Patients With Moderate to Severe Dyskinesia

NCT03956979 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 89

Last updated 2024-06-17

No results posted yet for this study

Summary

The current study will explore the efficacy, safety and tolerability of 2 dose combinations of JM-010 to determine the optimal doses of each component to be studied in confirmatory clinical trials.

Conditions

  • Dyskinesias

Interventions

DRUG

JM-010 group A

JM-010 fixed combination drug (Group A) + Placebo 2

DRUG

JM-010 group B

JM-010 fixed combination drug (Group B) + Placebo 1

DRUG

Placebos

Placebo 1 + Placebo 2

Sponsors & Collaborators

  • Bukwang Pharmaceutical

    collaborator INDUSTRY

  • Contera Pharma

    lead INDUSTRY

Principal Investigators

  • Contera Clinical Development · Contera Pharma

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-07-22
Primary Completion
2024-03-07
Completion
2024-03-21

Countries

  • France
  • Germany
  • Italy
  • South Korea
  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03956979 on ClinicalTrials.gov